APHIS Facility Requirements for Licensed Veterinary Biologic Establishments — Building and Equipment Standards for USDA-Licensed Vaccine and Biologic Manufacturers

Current Rule (2026)

What This Rule Does

If your company makes vaccines, serums, toxins, antitoxins, or any other biological product intended to prevent or treat animal diseases, you need a federal establishment license from APHIS before you can legally sell that product in interstate commerce. See APHIS Veterinary Biologics Program for the full licensing framework covering product approvals, serial release, and potency testing. Getting — and keeping — that license requires your manufacturing facility to meet a specific set of physical standards. 9 CFR Part 108 is the rulebook for those standards.

The underlying law is the Virus, Serum, and Toxin Act (21 U.S.C. §§ 151–159), which gives USDA authority to ensure that veterinary biologics are safe, pure, and potent. Congress passed the original version of this law in 1913, and the facility requirements in Part 108 have been the infrastructure backbone of that oversight ever since. Part 108 covers everything from how you draw your floor plans to the materials your walls must be made of and whether you have a signed water quality certification from your state on file with APHIS.

The practical upshot: APHIS cannot license your establishment — or keep it licensed — without reviewing and approving detailed documentation of every building and room where you make biological products. Physical deficiencies discovered during inspection are licensing violations, not just citations.

Key Mechanics

Documentation before the first vial ships. Under § 108.2, an applicant for an establishment license must submit three categories of documents to APHIS before licensure is granted: a plot plan (a to-scale map of every building at each land area associated with the license), blueprints (detailed floor plans of every building used in biologic preparation), and legends (booklets describing the activities in every room and the equipment used). All three must be on file with APHIS and accepted before the license issues. The address on each land area must exactly match what appears on the establishment license (§ 108.1).

What the drawings must show. Plot plans under § 108.3 must be drawn to standard scale with boundary lines, fences, walls, streets, and every building identified and numbered or lettered. Blueprints under § 108.4 must cover every floor where biologics are prepared, show all rooms in detail, identify the function of each room, code the location of all equipment, and depict drainage, electrical, and mechanical systems. The legends submitted under § 108.5 must correlate to both the plot plan and the blueprints, describe construction materials throughout, list every piece of equipment, explain waste disposal arrangements, and detail sanitation methods. This isn't back-office paperwork — APHIS inspectors use these documents as their inspection road map.

Keeping documentation current. § 108.6 requires that any changes to buildings or equipment trigger revised drawings before work is complete (or, for new construction, preliminary drawings may be submitted in advance). Every revision must identify what it supersedes. Under § 108.7, two copies of all drawings and revisions go to APHIS; one stamped-approved copy is returned to the establishment.

Physical construction standards. § 108.8 sets the floor (literally): all surfaces in biological product preparation areas — floors, walls, ceilings, partitions, posts, doors — must be made of materials that can be thoroughly cleaned. Room layouts must prevent cross-contamination between product lines; hallways must allow personnel and materials to move without passing through a preparation area. Separate, physically distinct rooms are required for work involving virulent or dangerous microorganisms. All preparation rooms need adequate ventilation, and hot and cold water must be available at adequate pressure throughout the facility.

Outer premises and animal facilities. Under § 108.10, loading docks, driveways, pens, and alleys must be drained and kept orderly. Any stables housing animals used in production or testing (common in serum manufacturing) must be ventilated, lighted, and kept sanitary. Accumulation of waste material in which vermin can breed is explicitly prohibited — APHIS inspectors will cite fly breeding habitat as a facility deficiency.

Water quality certification. § 108.11 requires each licensed establishment to file a certification from the appropriate state water pollution control agency confirming Clean Water Act § 401 compliance. This certification must be in place for each land area. Expanding to a new facility location means obtaining a new state-issued § 401 certification before APHIS will extend the license to cover that area.

How It Affects You

If you're a startup veterinary biologic manufacturer trying to bring a novel vaccine to market: facility documentation isn't something you prepare at the end of construction — it's something APHIS needs to review before you receive a license. Budget significant time for the drawing preparation process. A complete submission includes professionally drafted plot plans, room-by-room blueprints at American standard sizes, and detailed legend booklets. If APHIS returns your drawings with questions or deficiencies, the clock on your license application stops until you resolve them. Working with an architect experienced in APHIS requirements and pharmaceutical cGMP facilities from the project's design phase is not optional — it's a business-critical project dependency.

If you're an established licensed manufacturer planning a facility renovation: any change to a room's layout, function, or equipment requires revised blueprints and legends submitted to APHIS. This includes converting a storage room to a production room, adding a biosafety cabinet, or changing wall materials. Proceeding with construction before submitting preliminary drawings puts your establishment license at risk — the regulation authorizes preliminary submissions precisely so APHIS can flag design problems before you pour concrete. For major renovations, coordinate submission timing with your APHIS inspector of record.

If you're the quality or regulatory affairs lead at a licensed facility: your ongoing compliance obligation under Part 108 is continuous, not just at license renewal. APHIS inspectors arrive with your filed blueprints in hand and compare them against what they actually see. A room used for a purpose not described in the legend — even temporarily — is a documentation deficiency. Your internal audit calendar should include periodic verification that filed drawings match current facility use, and that your state § 401 water quality certification is current and on file.

If you manufacture products that involve virulent pathogens: the separate-room requirement in § 108.8 means you cannot improvise a work area inside a general production room using moveable barriers. The physical separation must be permanent and reflected in your blueprints. If biosafety containment requirements under other regulations (such as USDA Select Agent regulations at 9 CFR Part 121) interact with your Part 108 layout, ensure your blueprints satisfy both regulatory frameworks simultaneously — APHIS inspectors check for both.

If you're considering an acquisition of a licensed veterinary biologic facility: Part 108 compliance status is a material due-diligence item. If the facility holds patents on licensed biologics, also review patent term extension filings under APHIS Veterinary Biologic Patent Term Extension — remaining patent life affects the value of any product license. Review the buyer's filed blueprints against the actual physical facility. Outdated drawings, unreported modifications, or missing state water quality certifications are remediable — but each requires time and APHIS engagement. Treat open documentation deficiencies the same way you'd treat an unresolved FDA 483 observation.

Legal Authority

Virus, Serum, and Toxin Act (21 U.S.C. §§ 151–159) — the foundational statute enacted in 1913 and amended since. Each section delegates a specific power:

• 21 U.S.C. § 151 — Core prohibition: no person or company may prepare, sell, barter, or ship in interstate commerce any virus, serum, toxin, antitoxin, or analogous biological product intended for treating domestic animals that is worthless, contaminated, dangerous, or harmful. Preparation must occur at a licensed establishment in compliance with applicable rules.
• 21 U.S.C. § 152 — Import controls: no biological product for treating domestic animals may enter the United States if it is worthless, contaminated, dangerous, or harmful; importation requires a valid permit from USDA. See also Animal Health Protection Act for the broader APHIS import and disease exclusion framework.
• 21 U.S.C. § 153 — Import inspection: the Secretary of Agriculture may direct the Bureau of Animal Industry to inspect imported biological products; products found to be worthless, contaminated, dangerous, or harmful may be denied entry and destroyed.
• 21 U.S.C. § 154 — Rulemaking and licensing authority: the Secretary may issue rules to prevent harmful or contaminated biologics from entering commerce, and may issue, suspend, or revoke establishment and product licenses. This is the direct authority under which 9 CFR Part 108 was promulgated.
• 21 U.S.C. § 154a — Special (expedited) licenses: the Secretary may quickly grant a special license for emergencies, limited markets, local needs, or products made exclusively for intrastate use within a state.
• 21 U.S.C. § 155 — Import permits: USDA may issue or deny import permits for veterinary biologics.
• 21 U.S.C. § 156 — Inspection as a license condition: licenses for establishments that manufacture veterinary biologics must allow USDA officials to inspect the facility, the products, and the manufacturing process at any time. Licenses may be suspended or revoked following a hearing if violations are found.
• 21 U.S.C. § 157 — Inspection authority: USDA inspectors authorized by the Secretary may inspect any licensed establishment — buildings, equipment, and products — at any hour, day or night.
• 21 U.S.C. § 158 — Criminal penalties: violations of the Act are federal misdemeanors punishable by up to $1,000 in fines, up to one year of imprisonment, or both.
• 21 U.S.C. § 159 — Enforcement and congressional findings: enforcement procedures follow 21 U.S.C. §§ 672–674 (agricultural enforcement framework); Congress finds that covered products and activities are in interstate or foreign commerce and directly affect such commerce.

Implementing regulation:

• 9 CFR Part 108 — Facility requirements for licensed establishments: the operative regulatory text; §§ 108.1–108.11 cover applicability, documentation (plot plans, blueprints, legends), construction standards, outer premises, and water quality certification under Clean Water Act § 401

Recent Rulemakings

No major rulemakings to Part 108 have been published in the Federal Register in recent years. The facility standards have been stable for decades, reflecting APHIS's view that the core infrastructure requirements for biologic manufacturing facilities do not need frequent updating. The more active rulemaking front for this industry has been in adjacent areas — product licensing (9 CFR Parts 101–104), potency and purity testing (9 CFR Parts 113–114), and labeling (9 CFR Part 112, covered at APHIS Veterinary Biologic Packaging, Labeling, and Records) — rather than facility physical standards.

APHIS's Center for Veterinary Biologics (CVB) periodishes Veterinary Biologics Notices and Operational Policies that interpret these requirements in practice. These guidance documents, while not codified in the CFR, reflect current APHIS inspection expectations and are updated more frequently than the regulations themselves.

Pending Action

No active rulemaking or proposed rules targeting 9 CFR Part 108 are currently pending in the Federal Register. The facility standards have remained stable since the 1990s. Potential drivers of future revision include:

• Biosafety level alignment: growing legislative interest in biosafety and biosecurity (e.g., HR 4729, 119th Congress, which would codify Executive Order 14292 on biological research safety into statute) could prompt APHIS to update the physical containment requirements for virulent-microorganism rooms under § 108.8 to align with BSL-2/BSL-3 standards.
• Animal welfare interaction: any update to USDA animal welfare regulations affecting stables and animal holding facilities could require corresponding updates to § 108.10 outer-premises and stable standards.
• Digital documentation: APHIS has not yet moved Part 108 documentation (plot plans, blueprints, legends) to a fully electronic submission system; modernization of the licensing IT infrastructure could trigger a conforming amendment to the filing requirements in §§ 108.6–108.7.

DB query run 2026-05-11 — no Federal Register records matched 9 CFR Part 108 amendment activity.

Related topics: APHIS Veterinary Biologics Program · APHIS Veterinary Biologic Labeling and Records · APHIS Veterinary Biologic Patent Term Extension · Animal Health Protection Act · FDA Veterinary Animal Drug Regulations · USDA Agricultural Biosecurity